1. Home
  2. GMAB vs BBY Comparison

GMAB vs BBY Comparison

Compare GMAB & BBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GMAB
  • BBY
  • Stock Information
  • Founded
  • GMAB 1999
  • BBY 1966
  • Country
  • GMAB Denmark
  • BBY United States
  • Employees
  • GMAB N/A
  • BBY N/A
  • Industry
  • GMAB Biotechnology: Pharmaceutical Preparations
  • BBY Consumer Electronics/Video Chains
  • Sector
  • GMAB Health Care
  • BBY Consumer Discretionary
  • Exchange
  • GMAB Nasdaq
  • BBY Nasdaq
  • Market Cap
  • GMAB 17.4B
  • BBY 15.6B
  • IPO Year
  • GMAB N/A
  • BBY N/A
  • Fundamental
  • Price
  • GMAB $30.56
  • BBY $78.00
  • Analyst Decision
  • GMAB Strong Buy
  • BBY Buy
  • Analyst Count
  • GMAB 6
  • BBY 19
  • Target Price
  • GMAB $40.40
  • BBY $82.18
  • AVG Volume (30 Days)
  • GMAB 2.5M
  • BBY 3.2M
  • Earning Date
  • GMAB 11-06-2025
  • BBY 11-25-2025
  • Dividend Yield
  • GMAB N/A
  • BBY 4.89%
  • EPS Growth
  • GMAB 132.41
  • BBY N/A
  • EPS
  • GMAB 25.10
  • BBY 3.63
  • Revenue
  • GMAB $3,845,670,022.00
  • BBY $41,598,000,000.00
  • Revenue This Year
  • GMAB $24.92
  • BBY $1.64
  • Revenue Next Year
  • GMAB $15.97
  • BBY $1.33
  • P/E Ratio
  • GMAB $1.21
  • BBY $21.42
  • Revenue Growth
  • GMAB 29.57
  • BBY N/A
  • 52 Week Low
  • GMAB $17.24
  • BBY $54.99
  • 52 Week High
  • GMAB $33.65
  • BBY $95.49
  • Technical
  • Relative Strength Index (RSI)
  • GMAB 58.36
  • BBY 45.30
  • Support Level
  • GMAB $28.08
  • BBY $76.67
  • Resistance Level
  • GMAB $29.35
  • BBY $82.60
  • Average True Range (ATR)
  • GMAB 0.69
  • BBY 2.03
  • MACD
  • GMAB 0.03
  • BBY -0.75
  • Stochastic Oscillator
  • GMAB 95.93
  • BBY 15.81

About GMAB Genmab A/S ADS

Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

About BBY Best Buy Co. Inc.

With over $41 billion in consolidated 2024 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8% share of the North American market and around 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.

Share on Social Networks: